A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

References

• McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–04):1–34.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Mumps vaccines: WHO position paper. Wkly Epidemiol Rec. 2007;82(7):49–60.
   Google Scholar
• World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301–316.
   PubMedGoogle Scholar
• World Health Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(17):205–228.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Measles–United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(6):120–123.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Chapter 20: Rubella. In: Epidemiology and prevention of vaccine-preventable diseases. 13th ed. “The Pink Book”: Centers for Disease Control and Prevention, Washington DC; 2012. p. 325–340.
   Google Scholar
• Centers for Disease Control and Prevention. Mumps cases and outbreaks. Centers for disease control and prevention; 2018 Mar 6 [ accessed 2018 Mar 13]. https://www.cdc.gov/mumps/outbreaks.html.
   Google Scholar
• Centers for Disease Control and Prevention. Measles cases and outbreaks. Centers for disease control and prevention; 2017 Oct 13 [ accessed 2017 Oct 13]. https://www.cdc.gov/measles/cases-outbreaks.html.
   Google Scholar
• European Medicines Agency. Priorix. Annex III: Summary of product characteristics, labelling and package leaflet; 2012 [accessed 2018 Jan 15]. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Priorix_30/WC500124199.pdf.
   Google Scholar
• Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003;63(19):2107–2126. doi:10.2165/00003495-200363190-00012.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/164653/2005; 2006. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003870pdf.
   Google Scholar
• World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO/DRAFT; 2016 Jan 27 http://wwwwhoint/biologicals/Clinical_guidelines_27_January_2016pdf.
   Google Scholar
• Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2012;30(3):668–674. doi:10.1016/j.vaccine.2011.10.065.
   PubMed Web of Science ®Google Scholar
• Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, Schuerman L. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine. 2006;24(35–36):6120–6128. doi:10.1016/j.vaccine.2006.05.017.
   PubMed Web of Science ®Google Scholar
• Gillet Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446–453. doi:10.1016/j.vaccine.2008.10.064.
   PubMed Web of Science ®Google Scholar
• Lee H, Kim HW, Cho HK, Park EA, Choi KM, Kim KH. Reappraisal of MMR vaccines currently used in Korea. Pediatr Int. 2011;53(3):374–380. doi:10.1111/j.1442-200X.2010.03244.x.
   PubMed Web of Science ®Google Scholar
• Black S, Friedland LR, Schuind A, Howe B, for the GlaxoSmithKline DTaP–IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine. 2006;24(35–36):6163–6171. doi:10.1016/j.vaccine.2006.04.001.
   PubMed Web of Science ®Google Scholar
• Santos EM, Silva E Sa GR, Siqueira MM, Martins RM, Camacho LA, von Doellinger Vdos R, Maia ML. Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian national immunisation program. Mem Inst Oswaldo Cruz. 2014;109(3):335–339.
   PubMed Web of Science ®Google Scholar
• Amexis G, Fineschi N, Chumakov K. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology. 2001;287(1):234–241. doi:10.1006/viro.2001.1009.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, van der Zeijst B, Boog M, Hoitink C. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008;13:26.
   Google Scholar
• Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis. 2007;45(4):459–466. doi:10.1086/520028.
   PubMed Web of Science ®Google Scholar
• The MMR-162 Study Group. Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Hum Vaccin Immunother. 2018:1–11. doi:10.1080/21645515.2018.1502527.
   PubMed Web of Science ®Google Scholar
• Chen X, Bailleux F, Desai K, Qin L, Dunning AJ. A threshold method for immunological correlates of protection. BMC Med Res Methodol. 2013;13:29. doi:10.1186/1471-2288-13-29.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065. doi:10.1128/cvi.00131-10.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Correlates of vaccine-induced protection: methods and implications. Immunization Vaccines Biol. WHO/IVB/1301; 2013. http://appswhoint/iris/bitstream/handle/10665/84288/WHO_IVB_1301_engpdf;jsessionid=18887B1B09124C870BF9B348E23F93A1?sequence=1.
   Google Scholar
• Food and Drug Administration. Kinrix. Package insert; 2018 Feb 12. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241453.pdf.
   Google Scholar
• Food and Drug Administration. Varixax. Package insert; 2018 Feb 12. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142813.pdf.
   Google Scholar
• World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/GEN/939; 1993. http://appswhoint/iris/bitstream/handle/10665/70486/WHO_EPI_GEN_939_engpdf?sequence=1&isAllowed=y.
   Google Scholar
• Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012;31(8):e133–40. doi:10.1097/INF.0b013e318259fc8a.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO international standard pertussis antiserum (Human) 1st IS, NIBSC code: 06/140; 2013. http://www.nibsc.org/documents/ifu/06-140.pdf.
   Google Scholar